Search Result

Results for "

mouse primary hepatocytes

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (1) Amylases (1) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (2) Arrestin (1) Aryl Hydrocarbon Receptor (1) Asialoglycoprotein Receptor (ASGPR) (1) Bacterial (1) Carboxylesterase (CES) (1) Caspase (1) Constitutive Androstane Receptor (1) Cytochrome P450 (1) Dipeptidyl Peptidase (1) DNA/RNA Synthesis (1) Drug Derivative (3) Drug Metabolite (1) Fatty Acid Synthase (FASN) (1) FBPase (1) Ferroptosis (1) Free Fatty Acid Receptor (1) G protein-coupled Bile Acid Receptor 1 (1) GLUT (1) Glutathione Peroxidase (1) Glycosidase (1) HBV (3) HSP (1) IFNAR (1) Interleukin Related (1) KMO (1) LDLR (1) Lipase (1) Mitochondrial Metabolism (2) NF-κB (2) NOD-like Receptor (NLR) (1) P2Y Receptor (1) p38 MAPK (1) PGC-1α (1) PPAR (1) Pregnane X Receptor (PXR) (1) Pyroptosis (1) Reactive Oxygen Species (ROS) (3) SARS-CoV (1) Sirtuin (1) Small Interfering RNA (siRNA) (1) SOD (1) Sodium Channel (1) Somatostatin Receptor (1) Stearoyl-CoA Desaturase (SCD) (1) STING (1) TNF Receptor (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (2) Infection (6) Inflammation/Immunology (5) Metabolic Disease (13) Neurological Disease (1)

By Targets:

AMPK (1)

Amylases (1)

Angiotensin-converting Enzyme (ACE) (1)

Apoptosis (2)

Arrestin (1)

Aryl Hydrocarbon Receptor (1)

Asialoglycoprotein Receptor (ASGPR) (1)

Bacterial (1)

Carboxylesterase (CES) (1)

Caspase (1)

Constitutive Androstane Receptor (1)

Cytochrome P450 (1)

Dipeptidyl Peptidase (1)

DNA/RNA Synthesis (1)

Drug Derivative (3)

Drug Metabolite (1)

Fatty Acid Synthase (FASN) (1)

FBPase (1)

Ferroptosis (1)

Free Fatty Acid Receptor (1)

G protein-coupled Bile Acid Receptor 1 (1)

GLUT (1)

Glutathione Peroxidase (1)

Glycosidase (1)

HBV (3)

HSP (1)

IFNAR (1)

Interleukin Related (1)

KMO (1)

LDLR (1)

Lipase (1)

Mitochondrial Metabolism (2)

NF-κB (2)

NOD-like Receptor (NLR) (1)

P2Y Receptor (1)

p38 MAPK (1)

PGC-1α (1)

PPAR (1)

Pregnane X Receptor (PXR) (1)

Pyroptosis (1)

Reactive Oxygen Species (ROS) (3)

SARS-CoV (1)

Sirtuin (1)

Small Interfering RNA (siRNA) (1)

SOD (1)

Sodium Channel (1)

Somatostatin Receptor (1)

Stearoyl-CoA Desaturase (SCD) (1)

STING (1)

TNF Receptor (1)

By Research Areas:

Cancer (4)

Cardiovascular Disease (2)

Infection (6)

Inflammation/Immunology (5)

Metabolic Disease (13)

Neurological Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-159078

PolQi1	DNA/RNA Synthesis	Cancer
PolQi1 is a selective inhibitor targeting the Polθ domain of DNA polymerase. PolQi1 inhibits the Polθ-mediated microhomology end joining (TMEJ/alt-EJ) pathway, reducing insertion/deletion (Indels) and imprecise editing events during DNA repair. PolQi1 can enhance the efficiency and accuracy of homology-directed repair (HDR) or Prime editing, and reduce off-target effects; and in combination with DNA-PK inhibitor AZD-7648 (HY-111783), exert efficient genome editing capabilities with dual pathway regulation. PolQi1 can be mainly used in gene editing research (such as CRISPR-Cas9 or Prime editing system optimization) to improve the precision editing efficiency of difficult-to-edit cells (such as primary hepatocytes and mouse embryos) .

HY-177022

ALG-001075	HBV	Infection
ALG-001075, a capsid assembly modulator (CAM), is an orally active HBV inhibitor. ALG-001075 effectively blocks not only HBV DNA production but also extracellular HBsAg/HBeAg and intracellular HBV RNA in primary human hepatocytes. ALG-001075 shows pronounced reductions of circulating HBV DNA in the AAV-HBV mouse model. ALG-001075 can be used for the study of Chronic hepatitis B (CHB) .

HY-B1309

Metacetamol AMAP	Drug Derivative Mitochondrial Metabolism	Infection Cancer
Metacetamol (AMAP) is an analog of Acetaminophen (HY-66005). Metacetamol induces dose-dependent necrosis in primary hepatocytes via glutathione depletion, mitochondrial damage, and formation of mitochondrial protein adducts. Metacetamol derivatives act as anticancer and antibacterial agents. Metacetamol can be used in studies related to breast cancer, bacterial infections, and fungal infections (candidiasis) .

HY-N8599

Cichoriin 2 Publications Verification	Amylases Glycosidase Lipase Dipeptidyl Peptidase p38 MAPK PPAR P2Y Receptor NOD-like Receptor (NLR) SARS-CoV Pyroptosis GLUT Angiotensin-converting Enzyme (ACE) NF-κB	Infection Metabolic Disease Inflammation/Immunology
Cichoriin is an orally active coumarin glycoside with broad biological activities. Cichoriin exhibits inhibitory activities against α-amylase, α-glucosidase, pancreatic lipase and DPP-IV, with IC₅₀ values of 5.76, 2.94, 16.83 and 9.16 μg/mL, respectively. Cichoriin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) in mice by activating the AMPK signaling pathway. Cichoriin upregulates PPAR-γ in adipose tissue and alleviates obesity and associated cardiorenal injury in rats. Cichoriin blocks monosodium urate crystal-induced activation of the NLRP3 inflammasome and cell pyroptosis by inhibiting P2Y₁₄R (IC₅₀ = 8.47 nM). In silico virtual screening reveals that Cichoriin has a strong binding affinity for SARS-CoV-2 .

HY-G0006

Omeprazole sulfide 2 Publications Verification Ufiprazole	Drug Metabolite Aryl Hydrocarbon Receptor Bacterial	Infection Metabolic Disease
Omeprazole sulfide (Ufiprazole) is a metabolic degradation product of Omeprazole (HY-B0113). Omeprazole sulfide acts as a modulator of AhR. Omeprazole sulfide in cells with low CYP3A4 expression, functions as an AhR antagonist; however, in cells with high CYP3A4 expression, it is rapidly metabolized to Omeprazole, thereby acting as an AhR agonist. Omeprazole sulfide exhibits antibacterial activity when conjugated with silver nanoparticles (AgNPs). Omeprazole sulfide can be used in research on acid suppression and bacterial infections .

HY-110390

GR148672X	Carboxylesterase (CES) Free Fatty Acid Receptor Reactive Oxygen Species (ROS) Mitochondrial Metabolism Ferroptosis Apoptosis	Cardiovascular Disease Cancer
GR148672X is an inhibitor of carboxylesterase 1 (CES1) and hepatic microsomal triglyceride hydrolase (TGH). GR148672X blocks the catalytic activity of CES1, impairs the functions of triglyceride and cholesteryl ester lipase, reduces triglyceride mobilization and secretion, and decreases apolipoprotein B-100 secretion in primary rat hepatocytes. Under low-glucose conditions, GR148672X inhibits the survival of colorectal cancer cells by reducing free fatty acid availability, inducing toxic triglyceride accumulation, ROS production, mitochondrial damage, ferroptosis and apoptosis. GR148672X can be used in studies related to colorectal cancer and atherosclerosis .

HY-147645

FBPase-IN-2	FBPase	Metabolic Disease
FBPase-IN-2 (Compound HS36) is a covalent FBPase inhibitor with an IC₅₀ value of 0.15 μM for wild-type FBPase. FBPase-IN-2 inhibits glucose production in primary mouse hepatocytes via gluconeogenesis modulation. FBPase-IN-2 can be used for the research of type 2 diabetes mellitus .

HY-P991674

Brelovitug BJT-778	HBV	Infection Inflammation/Immunology
Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg). Brelovitug binds with high affinity to HBsAg purified from HBV serotypes ad and ay, with K_d values of 0.22 nM and 0.39 nM, respectively. Brelovitug binds with high affinity to HBsAg of HBV genotypes A, B, C and D, with IC₅₀ values of 0.07, 0.02, 0.02 and 0.07 nM, respectively. Brelovitug can be used in research related to chronic hepatitis B and chronic hepatitis D .

HY-153184

GalNAc-L96 free base	Asialoglycoprotein Receptor (ASGPR) Small Interfering RNA (siRNA)	Metabolic Disease
GalNAc-L96 free base is a conjugate of GalNAc and its ligand L96. When conjugated with the A-rich HCV sequence (H12), GalNAc-L96 free base binds potently to ASGPR, with a K_i value of 10.4 nM. GalNAc-L96 free base promotes siRNA delivery to hepatocytes .

HY-176274

FASN/SCD-IN-1	Fatty Acid Synthase (FASN) Stearoyl-CoA Desaturase (SCD) Reactive Oxygen Species (ROS) Interleukin Related TNF Receptor SOD LDLR Glutathione Peroxidase	Metabolic Disease Inflammation/Immunology
FASN/SCD-IN-1 is a Silybin (HY-N0779A) derivative, an orally active inhibitor of Fatty Acid Synthase (FASN)/Stearoyl-CoA Desaturase (SCD). FASN/SCD-IN-1 has shown in vitro activity in inhibiting lipid deposition, reducing FASN and SCD transcriptional levels, and exhibiting antioxidant, anti-inflammatory, and anti-fibrotic activities. FASN/SCD-IN-1 has demonstrated significant hepatoprotective effects in a rat model of acute liver injury. FASN/SCD-IN-1 ameliorates the pathological features of MASH liver, including steatosis, inflammation, and fibrosis in a mouse model of myeloproliferative steatohepatitis (MASH). FASN/SCD-IN-1 can be used to study MASH .

HY-N8107

Matairesinol monoglucoside 2 Publications Verification	STING IFNAR HBV	Infection
Matairesinol monoglucoside is a STING activator. Matairesinol monoglucoside modulates the STING-TBK1-IRF3 signaling axis, promotes STING transcriptional expression, increases TBK1 and IRF3 phosphorylation. Matairesinol monoglucoside induces IFN-α and IFN-β production, reduces HBV DNA, HBsAg, and HBeAg expression. Matairesinol monoglucoside can be used for the research of hepatitis b virus (hbv) infection .

HY-173033

MI-883	Pregnane X Receptor (PXR) Constitutive Androstane Receptor Cytochrome P450	Metabolic Disease
MI-883 is the orally active agonist for Constitutive Androstane Receptor (CAR, EC₅₀=73 nM) and the antagonist for Pregnane X Receptor (PXR, IC₅₀=0.1 μM). MI-883 stimulates CAR LBD assembly (EC₅₀=0.38 µM) and CAR3 variant activation (EC₅₀=0.074 µM), induces CYP2B6 mRNA expression in HepaRG and primary human hepatocytes. MI-883 inhibits basal PXR activity IC₅₀=2.03 µM) in transiently transfected HepG2 cells, blocks CYP3A4 mRNA expression in HepG2. MI-883 regulates cholesterol metabolism and bile acid excretion, improves hypercholesterolemia in mouse models .

HY-136855

MitoPBN	Sirtuin AMPK PGC-1α Apoptosis Reactive Oxygen Species (ROS)	Metabolic Disease
MitoPBN is a AMPK/SIRT3/PGC-1α axis modulator, reactive oxygen species scavenger and mitochondrial function enhancer. MitoPBN increases the phosphorylation level of AMPK, restores SIRT3 expression and reverses the down-regulation of PGC-1α, thereby promoting mitochondrial biogenesis. MitoPBN regulates glucose metabolism, reduces blood glucose by inhibiting hepatic gluconeogenesis and increasing hepatic glucose uptake, while scavenging mitochondrial superoxide anion/hydrogen peroxide, maintaining membrane potential and increasing ATP production. MitoPBN also reduces cell apoptosis, improves sperm motility, survival rate and membrane integrity, but may induce reductive stress in cryopreserved sperm at high concentrations. MitoPBN is widely applicable to research related to diabetes and type 2 diabetes .

HY-158160

LBA-3	Sodium Channel	Metabolic Disease
LBA-3 is a selective, orally active inhibitor for sodium-coupled citrate transporter SLC13A5, with an IC₅₀ of 67 nM. LBA-3 decreases levels of triglyceride and total cholesterol in oleic and palmitic acid (OPA)-stimulated AML12 cells, PCN-stimulated primary mouse hepatocytes and in mouse models, without detectable toxicity. LBA-3 is blood-brain barrier permeable .

HY-182302

SMTIN-P01	Drug Derivative HSP	Cancer
SMTIN-P01 is a TRAP1 inhibitor that is selective for cytosolic Hsp90 and accumulates in mitochondria. SMTIN-P01 binds to the ATP-binding site of TRAP1 as an ATP mimic, thereby inhibiting ATPase and foldase activities. SMTIN-P01 induces mitochondrial membrane depolarization and proteolytic degradation in cancer cells. SMTIN-P01 exhibits significant cytotoxicity, but shows extremely low toxicity to primary mouse hepatocytes, and does not interfere with SIRT3-related functions or the levels of cytosolic Hsp90 substrates. SMTIN-P01 has important application value in cancer-related research .

HY-111096

IDN-7314	Caspase	Cardiovascular Disease Metabolic Disease
IDN-7314 is a pan-Caspase inhibitor with an IC₅₀ of 0.2-7 nM against all tested Caspases. IDN-7314 abrogates Jo2-induced caspase-3/7 activity. IDN-7314 reduces the procoagulant activity of tissue factor in hepatocytes. IDN-7314 is applicable to research related to chemically induced hepatitis, fulminant liver failure and apoptotic liver injury .

HY-182905

SSTR5/TGR5-modulator-1	Somatostatin Receptor G protein-coupled Bile Acid Receptor 1	Metabolic Disease
SSTR5/TGR5-modulator-1 is an orally active and dual-target small molecule, balanced in vitro activity at human TGR5 and human SSTR5. SSTR5/TGR5-modulator-1 activates human TGR5 to promote cAMP accumulation. SSTR5/TGR5-modulator-1 blocks human SSTR5 to inhibit agonist-induced calcium mobilization. SSTR5/TGR5-modulator-1 improves glucose tolerance in mice. SSTR5/TGR5-modulator-1 alleviates gallbladder filling in mice at pharmacologically relevant doses. SSTR5/TGR5-modulator-1 has suboptimal physicochemical and metabolic properties.SSTR5/TGR5-modulator-1 can be used for the research of type 2 diabetes mellitus .

HY-182456

CHDI-340246	KMO	Neurological Disease
CHDI-340246 is an orally active kynurenine monooxygenase (KMO) inhibitor. CHDI-340246 blocks KMO activity, alters the metabolic flux of the kynurenine pathway, inhibits the production of 3-hydroxykynurenine and quinolinic acid, elevates the levels of kynurenine and kynurenic acid, and restores electrophysiological abnormalities in transgenic mouse models of Huntington's disease. CHDI-340246 can be used in studies related to Huntington's disease .

HY-149043

NIK-IN-1	NF-κB	Metabolic Disease
NIK-IN-1 (Compound 2) is an inhibitor of NF-κB-inducing kinase (NIK). NIK-IN-1 is used for research on hepatic inflammatory diseases and acute liver injury .

HY-181335

SKL1223	Arrestin	Metabolic Disease Inflammation/Immunology
SKL1223 is an orally effective thioredoxin-interacting protein (TXNIP) inhibitor with an IC₅₀ of 0.64 µM. SKL1223 interacts with the E-box region of the TXNIP promoter to inhibit TXNIP transcription and related signaling pathways. SKL1223 reduces hepatic glucose output. SKL1223 exerts hypoglycemic effects by regulating the action of glucagon, and modulates blood glucose levels in Streptozotocin (HY-13753)-induced and obesity-induced diabetic mice. SKL1223 can be used in the research of type 1 diabetes and type 2 diabetes .

HY-N13285

(-)-Epigallocatechin-4'-O-methylether (-)-EGC-4'-O-ME	Drug Derivative	Metabolic Disease Inflammation/Immunology
(-)-Epigallocatechin-4'-O-methylether ((-)-EGC-4'-O-ME) is an orally active natural phenolic catechin with antioxidant, free radical-scavenging and hepatoprotective activities. (-)-Epigallocatechin-4'-O-methylether interferes with radiation-induced free radical formation, scavenges DPPH free radicals, inhibits carbon tetrachloride-induced increases in serum GOT and GPT, suppresses carbon tetrachloride-induced TBA-RS formation, and counteracts carbon tetrachloride-induced hepatocyte toxicity. (-)-Epigallocatechin-4'-O-methylether binds specifically to human serum albumin. (-)-Epigallocatechin-4'-O-methylether can be used in studies related to liver injury .

Cat. No.	Product Name	Target	Research Area	Image

HY-P991674

Brelovitug BJT-778	HBV	Infection Inflammation/Immunology
Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg). Brelovitug binds with high affinity to HBsAg purified from HBV serotypes ad and ay, with K_d values of 0.22 nM and 0.39 nM, respectively. Brelovitug binds with high affinity to HBsAg of HBV genotypes A, B, C and D, with IC₅₀ values of 0.07, 0.02, 0.02 and 0.07 nM, respectively. Brelovitug can be used in research related to chronic hepatitis B and chronic hepatitis D .

Metacetamol AMAP	Structural Classification Monophenols Boswellia serrata Roxb. Phenols Plants Burseraceae Source Classification	Drug Derivative Mitochondrial Metabolism
Metacetamol (AMAP) is an analog of Acetaminophen (HY-66005). Metacetamol induces dose-dependent necrosis in primary hepatocytes via glutathione depletion, mitochondrial damage, and formation of mitochondrial protein adducts. Metacetamol derivatives act as anticancer and antibacterial agents. Metacetamol can be used in studies related to breast cancer, bacterial infections, and fungal infections (candidiasis) .

Cichoriin 2 Publications Verification	Infection Structural Classification Monophenols other families Classification of Application Fields Coumarins Phenols Phenylpropanoids Plants Disease Research Fields Source Classification	Amylases Glycosidase Lipase Dipeptidyl Peptidase p38 MAPK PPAR P2Y Receptor NOD-like Receptor (NLR) SARS-CoV Pyroptosis GLUT Angiotensin-converting Enzyme (ACE) NF-κB
Cichoriin is an orally active coumarin glycoside with broad biological activities. Cichoriin exhibits inhibitory activities against α-amylase, α-glucosidase, pancreatic lipase and DPP-IV, with IC₅₀ values of 5.76, 2.94, 16.83 and 9.16 μg/mL, respectively. Cichoriin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) in mice by activating the AMPK signaling pathway. Cichoriin upregulates PPAR-γ in adipose tissue and alleviates obesity and associated cardiorenal injury in rats. Cichoriin blocks monosodium urate crystal-induced activation of the NLRP3 inflammasome and cell pyroptosis by inhibiting P2Y₁₄R (IC₅₀ = 8.47 nM). In silico virtual screening reveals that Cichoriin has a strong binding affinity for SARS-CoV-2 .

Matairesinol monoglucoside 2 Publications Verification	Structural Classification Monophenols other families Classification of Application Fields Lignans Other Diseases Phenols Phenylpropanoids Plants Disease Research Fields Source Classification	STING IFNAR HBV
Matairesinol monoglucoside is a STING activator. Matairesinol monoglucoside modulates the STING-TBK1-IRF3 signaling axis, promotes STING transcriptional expression, increases TBK1 and IRF3 phosphorylation. Matairesinol monoglucoside induces IFN-α and IFN-β production, reduces HBV DNA, HBsAg, and HBeAg expression. Matairesinol monoglucoside can be used for the research of hepatitis b virus (hbv) infection .

(-)-Epigallocatechin-4'-O-methylether (-)-EGC-4'-O-ME	Structural Classification Ouratea Aubl. Phenols Polyphenols Plants Source Classification	Drug Derivative
(-)-Epigallocatechin-4'-O-methylether ((-)-EGC-4'-O-ME) is an orally active natural phenolic catechin with antioxidant, free radical-scavenging and hepatoprotective activities. (-)-Epigallocatechin-4'-O-methylether interferes with radiation-induced free radical formation, scavenges DPPH free radicals, inhibits carbon tetrachloride-induced increases in serum GOT and GPT, suppresses carbon tetrachloride-induced TBA-RS formation, and counteracts carbon tetrachloride-induced hepatocyte toxicity. (-)-Epigallocatechin-4'-O-methylether binds specifically to human serum albumin. (-)-Epigallocatechin-4'-O-methylether can be used in studies related to liver injury .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks